Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Calcium dobesilate

AEMPS

Capillary-stabilizing and venoactive agent

ATC code: C05BX01

Updated · Methodology

Indications

D

Chronic venous insufficiency

Adjunct

Used symptomatically for leg heaviness, edema, and pain in chronic venous insufficiency CEAP classes C0s–C3. Evidence is weak: the 2020 Cochrane meta-analysis of flavonoid and non-flavonoid venoactive agents reported moderate effect on pain and edema with low certainty. No benefit on hard outcomes (venous ulcer healing, disease progression) has been described. ESVS 2022 international guidance does not place this drug among first-line agents – the base treatment is compression and lifestyle change.

Sources

  1. AEMPS: Ficha técnica de Dobesilato cálcico (2024)
  2. Cochrane: Phlebotonics for venous insufficiency (2020)

ICD-10: I87.2 · ICD-11: BD74

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

D

Diabetic retinopathy

Not recommended

Historically used in non-proliferative diabetic retinopathy in Spain, Eastern Europe, and Latin America. No evidence base: the 2017 Cochrane review of calcium dobesilate in diabetic retinopathy showed no clinically meaningful effect on disease progression or visual preservation. ICO 2017 and 2024 do not list it among preferred agents. Foundation therapy for diabetic retinopathy: glycemic, blood pressure, and lipid optimization; for proliferative disease and macular edema – laser photocoagulation, intravitreal anti-VEGF (ranibizumab, aflibercept, bevacizumab).

Sources

  1. AEMPS: Ficha técnica de Dobesilato cálcico (2024)
  2. AAO: American Academy of Ophthalmology Preferred Practice Pattern – Diabetic Retinopathy (2019)

ICD-10: H36.0 · ICD-11: 9B71.0

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

A semisynthetic hydroquinone derivative. Claimed in vitro effects: reduced capillary permeability, antiplatelet activity, antioxidant and anti-inflammatory action. Mechanism data in humans are sparse. In Spain widely prescribed under the Doxium brand for chronic venous insufficiency and diabetic retinopathy – evidence on hard outcomes is limited.

Safety

Contraindications

  • Calcium dobesilate hypersensitivity
  • Pregnancy in T1

Serious adverse effects

  • Agranulocytosis (rare, isolated cases – EMA issued a 2014 warning)
  • Allergic reactions

Common adverse effects

  • Nausea
  • Epigastric pain
  • Diarrhea
  • Skin rash

Pregnancy: can you take Calcium dobesilate?

Avoid in T1 where possible due to limited data. For pregnancy venous symptoms, class 2 compression stockings are first-line.

Breastfeeding: can you take Calcium dobesilate?

Limited data. Use during lactation only when clearly indicated.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Evidence

Evidence for calcium dobesilate on hard clinical outcomes in CVI and diabetic retinopathy is limited. Use is justified only as short-term symptomatic adjunct to foundation therapy (compression in CVI, glycemic control in retinopathy); no disease modification should be expected. With persistent complaints, reconsider diagnosis and base therapy rather than escalating venoactive doses.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Calcium dobesilate used for?

Calcium dobesilate is evaluated for the following indications with varying evidence strength: Chronic venous insufficiency (evidence tier D), Diabetic retinopathy (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Calcium dobesilate?

Common side effects of Calcium dobesilate (≥ 1 in 100): Nausea, Epigastric pain, Diarrhea, Skin rash. See the Safety section for uncommon and serious reactions.

Is Calcium dobesilate safe during pregnancy?

Avoid in T1 where possible due to limited data. For pregnancy venous symptoms, class 2 compression stockings are first-line.

Is Calcium dobesilate compatible with breastfeeding?

Limited data. Use during lactation only when clearly indicated.

Who should not take Calcium dobesilate?

Calcium dobesilate is contraindicated in: Calcium dobesilate hypersensitivity; Pregnancy in T1. Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Diosmin/hesperidin, Hidrosmin